The upgrading and transformation of traditional Chinese medicine enterprises has accelerated, and a large number of enterprises are focusing on the big health industry

【Pharmaceutical Network Market Analysis】In recent years, under the influence of favorable policies, the development trend of traditional Chinese medicine is continuing to improve
.
Received by this news, related enterprises have also ushered in more development opportunities
.
It is reported that the performance of listed Chinese medicine companies in the first half of this year has no shortage of bright spots
.
According to the data, among the 73 A-share listed Chinese medicine companies, 47 achieved revenue growth in the first half of the year, of which 28 had revenues of more than 1 billion yuan, 5 had revenues of more than 5 billion yuan, and 2 had revenues of more than 10 billion yuan, namely Baiyun Mountain revenue of 37.
2 billion yuan and Yunnan Baiyao revenue of 18 billion yuan
.
While the performance is growing, some listed Chinese medicine companies are also adjusting and upgrading
their development strategies.
Among them, it is worth noting that many companies have taken the field of great health as the focus
of development.
For example, Yiling Pharmaceutical said that it will focus on the big health industry in
the future.
Therefore, in terms of product layout, the company will launch prescription drugs
from three dimensions: network disease (chronic disease), sub-health, and healthier.
On January 19 this year, Tailong Pharmaceutical also announced that the company intends to invest 50 million yuan to set up a wholly-owned subsidiary
in Yunnan.
According to the announcement, the soon-to-be-established wholly-owned subsidiary intends to be named "Yunnan Tailong Materia Medica Resources Development Co.
, Ltd.
", the purpose is mainly to rely on the characteristics of Yunnan traditional Chinese medicinal materials, natural plants and other industries, the use of modern advanced technology, through the extraction of Chinese herbal medicines, plant active ingredients, the development of health care products, food, cosmetics and other products, research and development of atomization inhalation mode in the application of Chinese herbal medicines, expand the herbal health atomization product module
.
In addition, Tongrentang has already begun to actively enter the field
of health care after insight into consumers' needs for health care.
It is reported that after adhering to the main direction of traditional Chinese medicine, it has formed five major plates with the pharmaceutical industry as the core, health care, medical pension, commercial retail, and international pharmaceutical industry as the support, and built a large health industry chain integrating planting (breeding), manufacturing, sales, medical treatment, health care, and research and development
.
On the whole, for Chinese medicine enterprises, the layout of the big health industry has become a trend
.
Industry analysts believe that under the influence of increasingly perfect policies, China's economic growth and consumption capacity, and the continuous intensification of medical care caused by the aging of the population, the big health industry will accelerate in China, and the market is expected to become a new growth point of
the national economy.
At the same time, a large number of traditional Chinese medicine enterprises are expected to usher in more opportunities
in this context.
However, it should be noted that compared with Western medicine companies, Chinese medicine companies pay more attention to brand inheritance, or innovate
in inheritance.
Therefore, for Chinese medicine enterprises, in the future, it is also necessary to accelerate the exploration of how to carry forward on the basis of inheritance and promote the high-quality development
of traditional Chinese medicine by continuously investing time, energy and funds.
Disclaimer: Under no circumstances does the information herein or the opinions expressed in this article constitute investment advice
to any person.